Compare · GNPX vs RCKT
GNPX vs RCKT
Side-by-side comparison of Genprex Inc. (GNPX) and Rocket Pharmaceuticals Inc. (RCKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GNPX and RCKT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- RCKT is the larger of the two at $235.6M, about 105.7x GNPX ($2.2M).
- GNPX has been more active in the news (9 items in the past 4 weeks vs 8 for RCKT).
- RCKT has more recent analyst coverage (25 ratings vs 0 for GNPX).
- Company
- Genprex Inc.
- Rocket Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $2.2M
- $235.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2015
- News (4w)
- 9
- 8
- Recent ratings
- 0
- 25
Genprex Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Latest GNPX
- Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer
- SEC Form 10-Q filed by Genprex Inc.
- Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
- SEC Form 8-K filed by Genprex Inc.
- Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
- SEC Form 8-K filed by Genprex Inc.
Latest RCKT
- SEC Form 144 filed by Rocket Pharmaceuticals Inc.
- CEO Gaurav Shah sold $6,795 worth of shares (3,020 units at $2.25), decreasing direct ownership by 0.29% to 1,053,574 units (SEC Form 4) to cover withholding tax
- General Counsel Martin Wilson sold $9,196 worth of shares (4,087 units at $2.25), decreasing direct ownership by 0.75% to 541,013 units (SEC Form 4) (for tax liability)
- Officer Chaudhuri Sarbani sold $11,337 worth of shares (4,872 units at $2.33), decreasing direct ownership by 2% to 257,937 units (SEC Form 4) (for tax liability)
- Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Rocket Pharmaceuticals Inc.
- Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
- General Counsel Wilson Martin sold $127,813 worth of shares (53,389 units at $2.39), decreasing direct ownership by 9% to 545,100 units (SEC Form 4) (tax liability)
- Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
- Rocket Pharmaceuticals upgraded by Goldman with a new price target